EMD-27826

Single-particle
3.6 Å
EMD-27826 Deposition: 12/08/2022
Map released: 26/04/2023
Last modified: 12/06/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-27826

Cryo-EM structure of the full-length human NF1 dimer

EMD-27826

Single-particle
3.6 Å
EMD-27826 Deposition: 12/08/2022
Map released: 26/04/2023
Last modified: 12/06/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: Full-length human NF1
Fitted models: 8e20 (Avg. Q-score: 0.323)

Deposition Authors: Darling JE, Merk A, Grisshammer R, Ognjenovic J
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.
PUBMED: 36689660
DOI: doi:10.1073/pnas.2208960120
ISSN: 1091-6490
ASTM: PNASA6
Abstract:
The majority of pathogenic mutations in the neurofibromatosis type I (NF1) gene reduce total neurofibromin protein expression through premature truncation or microdeletion, but it is less well understood how loss-of-function missense variants drive NF1 disease. We have found that patient variants in codons 844 to 848, which correlate with a severe phenotype, cause protein instability and exert an additional dominant-negative action whereby wild-type neurofibromin also becomes destabilized through protein dimerization. We have used our neurofibromin cryogenic electron microscopy structure to predict and validate other patient variants that act through a similar mechanism. This provides a foundation for understanding genotype-phenotype correlations and has important implications for patient counseling, disease management, and therapeutics.